MedPath

Carbetocin

Generic Name
Carbetocin
Brand Names
Duratocin
Drug Type
Small Molecule
Chemical Formula
C45H69N11O12S
CAS Number
37025-55-1
Unique Ingredient Identifier
88TWF8015Y
Background

Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.

Indication

Used to control postpartum hemorrhage and bleeding after giving birth.

Associated Conditions
Postpartum Haemorrhage (PPH), Uterine Atony
Clinical Trials
Related News

Carbetocin at Elective Cesarean Delivery Part 4

Not Applicable
Completed
Conditions
Postpartum Hemorrhage
Interventions
First Posted Date
2014-10-15
Last Posted Date
2015-05-27
Lead Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Target Recruit Count
110
Registration Number
NCT02264769
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN

Phase 4
Completed
Conditions
Complications; Cesarean Section
Anesthesia; Reaction
Interventions
First Posted Date
2014-08-20
Last Posted Date
2018-01-09
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
140
Registration Number
NCT02221531
Locations
🇨🇭

University Hospital Basel, Basel, Switzerland

Intramuscular Oxytocics: A Randomised Control Trial

Phase 3
Completed
Conditions
Post Partum Haemorrhage
Interventions
Drug: Syntometrine
First Posted Date
2014-08-15
Last Posted Date
2018-11-14
Lead Sponsor
North Bristol NHS Trust
Target Recruit Count
5798
Registration Number
NCT02216383
Locations
🇬🇧

Gloucestershire Hospitals NHS Trust, Gloucester, Gloucestershire, United Kingdom

🇬🇧

Royal United Hospital NHS Trust, Bath, Somerset, United Kingdom

🇬🇧

Great Western Hospital, Swindon, United Kingdom

and more 2 locations

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

Phase 3
Completed
Conditions
Severe Pre-eclampsia, Postpartum Condition or Complication
Interventions
First Posted Date
2014-03-14
Last Posted Date
2017-02-15
Lead Sponsor
khalid abd aziz mohamed
Target Recruit Count
60
Registration Number
NCT02086994
Locations
🇪🇬

Benha univesity hospital, Benha, Egypt

Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section

Phase 2
Completed
Conditions
Postpartum Hemorrhage
Interventions
First Posted Date
2014-03-06
Last Posted Date
2014-03-06
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
220
Registration Number
NCT02079558
Locations
🇮🇷

Infertility and Reproductive Health Research Center, Tehran, Iran, Islamic Republic of

The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

Phase 3
Completed
Conditions
Postpartum Hemorrhage
Interventions
First Posted Date
2014-02-04
Last Posted Date
2014-02-06
Lead Sponsor
Ain Shams University
Target Recruit Count
270
Registration Number
NCT02053922
Locations
🇪🇬

Ain Shams Maternity Hospital, Cairo, Egypt

Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section

Phase 4
Completed
Conditions
Postpartum Hemorrhage
Blood Loss
Interventions
Drug: Syntometrine
First Posted Date
2014-01-24
Last Posted Date
2021-06-24
Lead Sponsor
Cairo University
Target Recruit Count
300
Registration Number
NCT02044549
Locations
🇪🇬

Ahmed Maged, Cairo, Egypt

Analgesic Effect of Oxytocin Receptor Modulation

Not Applicable
Completed
Conditions
Hyperalgesia
Central Sensitization
Pain
Interventions
Drug: Placebo
First Posted Date
2013-08-07
Last Posted Date
2015-02-12
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
25
Registration Number
NCT01918475
Locations
🇨🇭

University Department of Anesthesiology and Pain Therapy, Bern University Hospital, Bern, Switzerland

Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption

Phase 4
Conditions
CARBETOCIN FOR PREVENTION OF PLACENTAL RETAINED
Interventions
First Posted Date
2013-04-09
Last Posted Date
2013-10-08
Lead Sponsor
Wafaa Uthman Ahmed
Target Recruit Count
140
Registration Number
NCT01827124
Locations
🇪🇬

Ain Shams university maternity hospital department of obstetrics and gynacology, Cairo, Tertiary, Egypt

Carbetocin at Cesarean Delivery for Labor Arrest

Not Applicable
Completed
Conditions
Postpartum Hemorrhage
Interventions
First Posted Date
2012-11-12
Last Posted Date
2013-05-30
Lead Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Target Recruit Count
40
Registration Number
NCT01725243
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy